Methergin

Methylergometrine Maleate, the active ingredient in Methergin, is an ergot alkaloid presented as an oral formulation for oral use. It is employed to prevent and treat postpartum hemorrhage by stimulating uterine contraction in postpartum women.

GNH USA supplies Methergin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methergin is a uterotonic agent used in the management of postpartum bleeding and related uterine conditions. - Postpartum hemorrhage (prevention): reduces the risk of excessive bleeding after delivery. - Postpartum hemorrhage (treatment): contracts the uterus to stop bleeding caused by uterine atony. - Uterine atony (treatment): restores uterine tone when the uterus fails to contract adequately after birth.

Methergin may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Hypertension: temporary rise in blood pressure. - Abdominal pain: cramping in the lower abdomen.

Serious or Rare Side Effects: - Coronary artery spasm: severe chest pain requiring immediate care. - Myocardial infarction: heart attack risk in susceptible patients. - Stroke: neurological emergency due to vascular constriction. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Uterine rupture: rare but life‑threatening tearing of the uterine wall.

Use Methergin only under medical supervision with attention to cardiovascular and obstetric status. - Cardiovascular assessment: evaluate blood pressure and heart disease before administration. - Pregnancy contraindication: not for use during pregnancy due to fetal risk. - Breastfeeding: avoid if the infant is nursing, as drug may be excreted in milk. - Drug interactions: review concurrent medications for potential additive effects. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Methergin can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Ergot‑derived drugs: additive vasoconstriction may cause severe hypertension. - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Sympathomimetic agents: potentiation of vasoconstrictive effects.

Moderate Interactions (Monitor Closely): - Antihypertensive medications: may blunt intended uterine contraction. - Antipsychotics with dopamine antagonism: possible additive central effects.